Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles.
-
Mohamed MO, Kontopantelis E, Alasnag M, Abid L, Banerjee A, Sharp ASP, Bourantas C, Sirker A, Curzen N, Mamas MA. Impact of Society Guidelines on Trends in Use of Newer P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2024 05 07; 13(9):e034414.
-
Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzatti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, Valgimigli M. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. Int J Cardiol. 2021 08 15; 337:1-8.
-
Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs. 2021 Sep; 21(5):483-486.
-
Sabouret P, Savage MP, Fischman D, Costa F. Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. Am J Cardiovasc Drugs. 2021 Jan; 21(1):21-34.
-
Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. Am J Cardiol. 2020 11 15; 135:154-165.
-
Nagalla S, Sarode R. Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy. Transfus Med Rev. 2019 04; 33(2):92-97.
-
Savage MP, Fischman DL. Clopidogrel Hypersensitivity: Overview of the Problem. Curr Vasc Pharmacol. 2019; 17(2):108-109.
-
Vishnevsky A, Savage MP, Fischman DL. Treatment of Clopidogrel Hypersensitivity: The Jefferson Approach. Curr Vasc Pharmacol. 2019; 17(2):123-126.
-
Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, Shaw CA, Edelstein LC, Bray PF. The protease-activated receptor?4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor?4 desensitization, and is blocked by non-competitive P2Y12 inhibition. J Thromb Haemost. 2018 12; 16(12):2501-2514.
-
Faggioni M, Baber U, Chandrasekhar J, Sartori S, Claessen BE, Rao SV, Vogel B, Effron MB, Poddar K, Farhan S, Kini A, Weintraub W, Toma C, Sorrentino S, Weiss S, Snyder C, Muhlestein JB, Kapadia S, Keller S, Strauss C, Aquino M, Baker B, Defranco A, Pocock S, Henry T, Mehran R. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol. 2019 Jan 15; 275:31-35.